2015
DOI: 10.1016/j.ijpharm.2015.06.045
|View full text |Cite
|
Sign up to set email alerts
|

Controlled release floating multiparticulates of metoprolol succinate by hot melt extrusion

Abstract: Bradford Scholars -how to deposit your paper Overview Copyright check• Check if your publisher allows submission to a repository.• Use the Sherpa RoMEO database if you are not sure about your publisher's position or email openaccess@bradford.ac.uk.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
7
0

Year Published

2016
2016
2019
2019

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(8 citation statements)
references
References 47 publications
1
7
0
Order By: Relevance
“…allowing to cool to room temperature (Bhalekar et al, 2009). There have been similar investigations reported in the literature on lipid crystallization behavior (Malode et al, 2015; Windbergs et al, 2009).…”
Section: Resultssupporting
confidence: 85%
“…allowing to cool to room temperature (Bhalekar et al, 2009). There have been similar investigations reported in the literature on lipid crystallization behavior (Malode et al, 2015; Windbergs et al, 2009).…”
Section: Resultssupporting
confidence: 85%
“…The structure of the pellets allowed immediate flotation in0.1 N HClduring12-24 hour periods and also theophylline delivery in prolonged fashion (Vo et al, 2015). Malode et al(2015), designed multiple-unit floating delivery system containing metoprolol succinate as model drug incombination withthree different polymers (Eudragit RS PO, polyethylene oxide -PEO WSR 303 and HPMC K100M) and sodium bicarbonate as in situ gas generator. Units based solelyon Eudragit RS PO did not float, even though sodium bicarbonate was present.…”
Section: Targeted Oral Dosage Formsmentioning
confidence: 99%
“…Introducing HPMC in the system in amounts of 15% maintained the short floating lag time but also significantly increased the total floating time up to 12h while delivering the API in continuous manner by zero order kinetics. The optimal formulation was unaffected by storage conditions with regard to floating properties and drug delivery (Malode et al, 2015).…”
Section: Targeted Oral Dosage Formsmentioning
confidence: 99%
“…Controlled-release (Almeida et al, 2011;Grassi et al, 2003;Phaechamud, Thongpin, Choncheewa, 2012;Sharma, Amin, 2013;Tran et al, 2011;Verhoeven, Vervaet, Remon, 2006);  Gastro-retentive/floating systems (Malode, Paradkar, Devarajan, 2015);  High drug loading in immediate-release systems (Cai et al, 2013);  Combination of different delivery systems (Dierickx et al, 2012;Dierickx, Remon, Vervaet, 2013);  Obtention of immediate-release systems, with a focus on masking drug flavor (Gryczke et al, 2011;Issa et al, 2012b);  Improvement in dissolution of poorly soluble drugs (Deng et al, 2012;Kalidova, Fischbach, Kleinebudde, 2012 Controlled-release (Aleksovski et al, 2015;Lopes et al, 2006;Tomuta, Leucuta, 2007);  Combination of different delivery systems (Souza, Goebel, Andreazza, 2013);  Colonic release (Vemula, 2015);  Ocular bio-adhesives (Bozdag et al, 2010;Weyenberg et al, 2003;Weyenberg et al, 2006);  Gastro-retentive/floating systems (Goole et al, 2008;Hauptstein et al, 2013;Katakam et al, 2014);  Obtention of immediate-release systems, with a focus on masking drug flavor (Eckert, Pein, Breitkreutz, 2014);…”
mentioning
confidence: 99%